**Supplementary table 1:** Baseline clinical and virological features of patients with HCV cirrhosis included in the training cohort and validation cohort

|  |  |  |
| --- | --- | --- |
|  | **Training cohort****(326 pts)** | **Validation cohort****(1,055 pts)** |
| **Age (yrs) mean, SD** | 66.1 ± 10.3 | 65.9 ± 10.6 |
| **Male gender (%)** | 198 (60.7%) | 628 (59.5%) |
| **BMI (Kg/m2)** | 26.1 ± 3.8 | 25.9 ± 3.9 |
| **Bilirubin (mean, SD) mg/dl** | 1.1 ± 0.6 | 1.1 ± 0.7 |
| **Albumin (mean, SD) g/dl** | 3.8 ± 0.5 | 3.8 ± 0.5 |
| **INR** | 1.1 ± 0.2 | 1.1 ± 0.2 |
| **Child Pugh B(%)** | 31 (9.5%) | 125 (11.8%) |
| **AST (mean, SD) U/L** | 81.1 ± 45.9 | 84.9 ± 53.1 |
| **ALT (mean, SD) U/L** | 85.9 ± 51.8 | 89.3 ± 61.1 |
| **Plt (x 109) (mean, SD)** | 120.4 ± 57.7 | 120.9 ± 60.2 |
| **PLT > 150 x109 (%)** | 83 (25.5%) | 258 (24.5%) |
| **PLT > 120 x109 (%)** | 146 (44.8%) | 450 (42.7%) |
| **Portal vein (PV) mm (means, SD)** | 11.6 ± 1.8 | 12.2 ± 2.0 \* |
| **Spleen diameter (SD) cm (mean, SD)** | 14.0 ± 2.7 | 13.6 ± 2.4 \* |
| **TE (mean,SD kPa)** | 23.3 ± 12.5 | 25.1 ± 13.1 |
| **TE < 20** | 161 (49.4%) | 459 (43.5%) |
| **TE < 25** | 213 (65.3%) | 633 (60%) |
| **No EV (%)\*\*****Small EV (%)****Medium/Large EV (%)** | 93 (28.5)204 (62.6)29 (8.9%) | 608 (57.6)347 (32.9)100 (9.5%) |

\* US available in 325 (99.7) and 957 (90.7) patients of training and validation cohort respectively

\*\* significant difference between the two groups by Chi-square test, p < 0.001

**Supplementary table 2.** Need for endoscopy according to Baveno VI, Expanded Baveno VI and RESIST-HCV criteria in training and validation cohorts.

|  |  |  |
| --- | --- | --- |
|  | **Training cohort (326 pts)** | **Validation cohort (1,055 pts)** |
|   | Baveno VI | Expanded Baveno VI | RESIST HCV | RESIST HCV + TE | Baveno VI | Expanded Baveno VI | RESIST HCV | RESIST HCV + TE |
| Saved EDS% | 16 | 37,7 | 36,5 | 27,6 | 15,5 | 35.4 | 30 | 22,7 |
| False negative rate % | 1.9 | 2.4 | 0.8 | 1.1 | 2.5 | 2.7 | 1.9 | 2.1 |
| NPV % | 98.1 | 97.6 | 99.2 | 98.9 | 97.5 | 97.3 | 98.1 | 97.9 |

**Supplementary table 3:** Diagnostic performance characteristics of non invasive criteria for rule out medium/large varices

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **AUC** | **SE a** | **95% CI b** | **Sensitivity(%)** | **Specificity (%)** |
| Baveno VI | 0.565 | 0.00999 | 0.538 to 0.591 | 96.1 | 16.9 |
| Expanded Baveno VI | 0.643 | 0.0149 | 0.618 to 0.669 | 90.0 | 38.7 |
| RESIST-HCV | 0.644 | 0.0120 | 0.618 to 0.669 | 94.6 | 34.1 |
| RESIST-HCV + TE | 0.626 | 0.0225 | 0.600 to 0.651 | 61.5 | 63.6 |